Developing Abuse-Deterrent

Medications to Reduce

the Potential for Harm

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders.

Prescription Stimulant Abuse is a Large and Growing Concern

5+ million

adolescents and adults misuse prescription stimulants annually1

From 2004 – 2011, emergency department visits due to non-medical use of stimulants2

Increased 4.7x

From 2010 – 2017, deaths associated with prescription stimulants3

Increased 5x

Sources: 1. SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2018; 2. Drug Abuse Warning Network, 2011; 3. Black, CPDD, 2020.

Our Technology is Designed to Resist Manipulation for Snorting and Provide Barriers to Injection

Our lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine  designed to deter attempts to crush and snort and provides barriers to injection.

Quick Links

Corporate Presentation
Corporate Fact Sheet
Sign Up for Alerts